Restricted accessResearch articleFirst published online 2020-06
Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes
Solid tumors have complex biology and structure comprising cancer cells, stromal cells, and the extracellular matrix. While most therapeutics target the cancer cells, recent data suggest that cancer cell behavior and response to treatment are markedly influenced by the tumor microenvironment (TME). In particular, the cancer-associated fibroblasts (CAFs) are the most abundant stromal cells, and play a significant contextual role in shaping tumor initiation, progression, and metastasis. CAFs have therefore emerged as part of the next-generation cancer drug design and discovery innovation strategy. We report here new findings on differential expression and prognostic significance of CAF markers in several cancers. We utilized two publicly available resources: The Cancer Genomic Atlas and Gene Expression Profiling Interactive Analysis. We examined the expression of CAF markers, ACTA2, S100A4, platelet-derived growth factor receptor-beta [PDGFR-β], CD10, and fibroblast activation protein-alpha (FAP-α), in tumor tissues versus the adjacent normal tissues. We found that CAF markers were differentially expressed in various different tumors such as colon, breast, and esophageal cancers and melanoma. No CAF marker is expressed in the same pattern in all cancers, however. Importantly, we report that patients with colon adenocarcinoma and esophageal carcinoma expressing high FAP-α and CD10, respectively, had significantly shorter overall survival, compared with those with low levels of these CAF markers (p < 0.05). We call for continued research on TME biology and clinical evaluation of the CAF markers ACTA2, S100A4, PDGFR-β, CD10, and FAP-α in relation to prognosis of solid cancers in large population samples. An effective cancer drug design and discovery roadmap in the 21st century ought to be broadly framed, and include molecular targets informed by both cancer cell and TME variations.
Get full access to this article
View all access options for this article.
References
1.
AkrishSJ, RachmielA, SaboE, VeredM, and Ben-IzhakO. (2016). Cancer associated fibroblasts are an infrequent finding in the microenvironment of proliferative verrucous leukoplakia associated squamous cell carcinoma. J Oral Pathol Med, 46, 353–358.
2.
AmornsupakK, InsawangT, Thuwajit PP OC, EcclesSA, and ThuwajitC. (2014). Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer, 14, 955.
3.
BaiX, ChenY, HouX, HuangM, and JinJ. (2016). Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev, 48, 541–567.
4.
BarbazanJ, and Matic VignjevicD. (2019). Cancer associated fibroblasts: Is the force the path to the dark side?. Curr Opin Cell Biol, 56, 71–79.
5.
BegicevicRR, and FalascaM. (2017). abc transporters in cancer stem cells: Beyond chemoresistance. Int J Mol Sci 18, pii:. E2362.
6.
BhattVR, and VoseJM. (2014). Hematopoietic stem cell transplantation for non-Hodgkin lymphoma. Hematol Oncol Clin North Am, 28, 1073–1095.
7.
BorleyJ, and BrownR. (2015). Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Ann Med, 47, 359–369.
8.
BorrielloL, NakataR, SheardMA, et al. (2017). Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells. Cancer Res, 77, 5142–5157.
9.
BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
10.
BrunenD, WillemsSM, KellnerU, MidgleyR, SimonI, and BernardsR. (2013). TGF-beta: An emerging player in drug resistance. Cell Cycle, 12, 2960–2968.
11.
CamoraniS, HillBS, CollinaF, et al. (2018). Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRbeta aptamer. Theranostics, 8, 5178–5199.
12.
Castello-CrosR, KhanDR, SimonsJ, ValianouM, and CukiermanE. (2009). Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer, 9, 1471–2407.
13.
ChenM, XiangR, WenY, et al. (2015). A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts. Sci Rep, 5, 14421.
14.
ChenX, and SongE. (2019). Turning foes to friends: Targeting cancer-associated fibroblasts. Nat Rev Drug Discov, 18, 99–115.
15.
ChengY, WangK, MaW, et al. (2015). Cancer-associated fibroblasts are associated with poor prognosis in esophageal squamous cell carcinoma after surgery. Int J Clin Exp Med, 8, 1896–1903.
16.
DenlingerCE, and ThompsonRK. (2012). Molecular basis of esophageal cancer development and progression. Surg Clin North Am, 92, 1089–1103.
17.
DevesaSS, BlotWJ, and FraumeniJFJr. (1998). Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer, 83, 2049–2053.
18.
DhomenN, Reis-FilhoJS, Da Rocha DiasS, et al. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell, 15, 294–303.
19.
DuperretEK, TrautzA, AmmonsD, et al. (2018). Alteration of the tumor stroma using a consensus dna vaccine targeting fibroblast activation protein (FAP) synergizes with antitumor vaccine therapy in mice. Clin Cancer Res, 24, 1190–1201.
20.
DzoboK. (2019). Epigenomics-guided drug development: Recent advances in solving the cancer treatment “jigsaw puzzle.”. OMICS, 23, 70–85.
21.
DzoboK. (2020). Taking a full snapshot of cancer biology: Deciphering the tumor microenvironment for effective cancer therapy in the Oncology Clinic. OMICS, 24, 175–179.
22.
DzoboK, HassenN, SenthebaneDA, et al. (2018a). Chemoresistance to cancer treatment: Benzo-alpha-pyrene as friend or foe?. Molecules 23, pii:. E930.
23.
DzoboK, LeanerVD, and ParkerMI. (2012). Feedback regulation of the alpha2(1) collagen gene via the Mek-Erk signaling pathway. IUBMB Life, 64, 87–98.
24.
DzoboK, LeanerVD, and ParkerMI. (2014). Absence of feedback regulation in the synthesis of COL1A1. Life Sci, 103, 25–33.
25.
DzoboK, SenthebaneDA, RoweA, et al. (2016). Cancer stem cell hypothesis for therapeutic innovation in clinical oncology? Taking the root out, not chopping the leaf. OMICS, 20, 681–691.
26.
DzoboK, SenthebaneDA, ThomfordNE, RoweA, DandaraC, and ParkerMI. (2018b). Not everyone fits the mold: Intratumor and intertumor heterogeneity and innovative cancer drug design and development. OMICS, 22, 17–34.
DzoboK, ThomfordNE, and SenthebaneDA. (2019b). Targeting the versatile wnt/beta-catenin pathway in cancer biology and therapeutics: From concept to actionable strategy. OMICS, 23, 517–538.
29.
EaswaranH, TsaiHC, and BaylinSB. (2014). Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell, 54, 716–727.
30.
FerlayJ, ColombetM, SoerjomataramI, et al. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 144, 1941–1953.
31.
GandhiJ, AfridiA, VatsiaS, et al. (2018). The molecular biology of prostate cancer: Current understanding and clinical implications. Prostate Cancer Prostatic Dis, 21, 22–36.
32.
GerliMFM, GuyetteJP, Evangelista-LeiteD, GhoshhajraBB, and OttHC. (2018). Perfusion decellularization of a human limb: A novel platform for composite tissue engineering and reconstructive surgery. PLoS One, 13, e0191497.
33.
GrassoCS, WuYM, RobinsonDR, et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature, 487, 239–243.
34.
HaSY, YeoS-Y, XuanY-H, and KimS-H. (2014). The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma. PLoS One, 9, e99955.
35.
HuangB, HuangM, and LiQ. (2019). Cancer-associated fibroblasts promote angiogenesis of hepatocellular carcinoma by VEGF-mediated EZH2/VASH1 Pathway. Technol Cancer Res Treat, 18, 1533033819879905.
36.
HuhtaniemiR, OksalaR, KnuuttilaM, et al. (2018). Adrenals contribute to growth of castration-resistant VCaP prostate cancer xenografts. Am J Pathol, 188, 2890–2901.
37.
IppolitoL, MorandiA, TaddeiML, et al. (2019). Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer. Oncogene, 38, 5339–5355.
38.
JiangGM, XuW, DuJ, et al. (2016). The application of the fibroblast activation protein alpha-targeted immunotherapy strategy. Oncotarget, 7, 33472–33482.
39.
KishiM, AonoY, SatoS, et al. (2018). Blockade of platelet-derived growth factor receptor-beta, not receptor-alpha ameliorates bleomycin-induced pulmonary fibrosis in mice. PLoS One, 13, e0209786.
40.
KuboN, ArakiK, KuwanoH, and ShirabeK. (2016). Cancer-associated fibroblasts in hepatocellular carcinoma. World J Gastroenterol, 22, 6841–6850.
41.
KyptaRM, and WaxmanJ. (2012). Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol, 9, 418–428.
42.
LeeH-O, MullinsSR, Franco-BarrazaJ, ValianouM, CukiermanE, and ChengJD. (2011). FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer, 11, 245.
43.
LiY, WangR, XiongS, et al. (2019). Cancer-associated fibroblasts promote the stemness of CD24(+) liver cells via paracrine signaling. J Mol Med (Berl), 97, 243–255.
44.
LinB, SongX, YangD, BaiD, YaoY, and LuN. (2018). Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1. Gene, 654, 77–86.
45.
LoA, WangLS, SchollerJ, et al. (2015). Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res, 75, 2800–2810.
46.
LopezJI, ErrarteP, ErramuzpeA, et al. (2016). Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma. Hum Pathol, 54, 100–105.
47.
LuC, RongD, ZhangB, et al. (2019). Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: Challenges and opportunities. Mol Cancer, 18, 130.
48.
MerrittEK, HammersDW, TierneyM, SuggsLJ, WaltersTJ, and FarrarRP. (2010). Functional assessment of skeletal muscle regeneration utilizing homologous extracellular matrix as scaffolding. Tissue Eng Part A, 16, 1395–1405.
49.
RidgeSM, BhattacharyyaD, DervanE, et al. (2018). Secreted factors from metastatic prostate cancer cells stimulate mesenchymal stem cell transition to a pro-tumourigenic ‘activated’ state that enhances prostate cancer cell migration. Int J Cancer, 142, 2056–2067.
50.
SandbergTP, StuartMPME, OostingJ, TollenaarRaEM, SierCFM, and MeskerWE. (2019). Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer. BMC Cancer, 19, 284.
51.
SenthebaneD, JonkerT, RoweA, et al. (2018). The role of tumor microenvironment in chemoresistance: 3D extracellular matrices as accomplices. Int jmol sci, 19, 2861.
52.
SenthebaneDA, RoweA, ThomfordNE, et al. (2017). The role of tumor microenvironment in chemoresistance: To survive, keep your enemies closer. Int J Mol Sci, 18, 1586.
53.
SicariBM, RubinJP, DearthCL, et al. (2014). An acellular biologic scaffold promotes skeletal muscle formation in mice and humans with volumetric muscle loss. Sci Transl Med, 6, 234ra258.
54.
StolzW, SchmoeckelC, LandthalerM, and Braun-FalcoO. (1989). Association of early malignant melanoma with nevocytic nevi. Cancer, 63, 550–555.
55.
TansiFL, RugerR, BohmC, et al. (2016). Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases. Biomaterials, 88, 70–82.
56.
TaoL, HuangG, SongH, ChenY, and ChenL. (2017). Cancer associated fibroblasts: An essential role in the tumor microenvironment. Oncol Lett, 14, 2611–2620.
57.
TeichgraberV, MonasterioC, ChaitanyaK, et al. (2015). Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. Adv Med Sci, 60, 264–272.
58.
TommeleinJ, VersetL, BoterbergT, DemetterP, BrackeM, and De WeverO. (2015). Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol, 5, 63.
59.
TorreLA, BrayF, SiegelRL, FerlayJ, Lortet-TieulentJ, and JemalA. (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87–108.
60.
TroxellML, and HigginsJP. (2016). Renal cell carcinoma in kidney allografts: Histologic types, including biphasic papillary carcinoma. Hum Pathol, 57, 28–36.
61.
TruffiM, SorrentinoL, MonieriM, et al. (2018). Inhibition of fibroblast activation protein restores a balanced extracellular matrix and reduces fibrosis in Crohn's disease strictures ex vivo. Inflamm Bowel Dis, 24, 332–345.
62.
VermassenT, De MeulenaereA, Van De WalleM, and RotteyS. (2017). Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma. Acta Clin Belg, 72, 12–18.
63.
WangD, and DuboisRN. (2015). Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis, 36, 1085–1093.
64.
WangLC, LoA, SchollerJ, et al. (2014). Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res, 2, 154–166.
65.
WangX, ZhangW, SunX, LinY, and ChenW. (2018). Cancer-associated fibroblasts induce epithelial-mesenchymal transition through secreted cytokines in endometrial cancer cells. Oncol Lett, 15, 5694–5702.
66.
WilliamsonSR, and ChengL. (2016). Clear cell renal cell tumors: Not all that is “clear” is cancer. Urol Oncol, 34, 292.e217–222.
YangY, DengY, ChenX, et al. (2018). Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism. Toxicol Lett, 295, 88–98.
69.
ZengJ-H, LuW, LiangL, et al. (2019). Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: An investigation based on RNA-sequencing data. J Transl Med, 17, 281.
70.
ZhangH, XieC, YueJ, et al. (2016). Cancer-associated fibroblasts mediated chemoresistance by a FOXO1/TGFbeta1 signaling loop in esophageal squamous cell carcinoma. Mol Carcinog, 56, 1150–1163.
71.
ZhangR, QiF, ZhaoF, et al. (2019). Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. Cell Death Dis, 10, 019–1435.
72.
ZhangY, and ErtlHC. (2016). Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. Oncotarget, 7, 23282–23299.
73.
ZhaoZ, BaiS, WangR, et al. (2019). Cancer-associated fibroblasts endow stem-like qualities to liver cancer cells by modulating autophagy. Cancer Manag Res, 11, 5737–5744.
74.
ZhengX, TurkowskiK, MoraJ, et al. (2017). Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget, 8, 48436–48452.
75.
ZhouL, YangK, AndlT, WickettRR, and ZhangY. (2015). Perspective of targeting cancer-associated fibroblasts in melanoma. J Cancer, 6, 717–726.
76.
ZhouL, YangK, DunawayS, et al. (2018). Suppression of MAPK signaling in BRAF-activated PTEN-deficient melanoma by blocking beta-catenin signaling in cancer-associated fibroblasts. Pigment Cell Melanoma Res, 31, 297–307.
77.
ZhouL, YangK, WickettRR, KadekaroAL, and ZhangY. (2016). Targeted deactivation of cancer-associated fibroblasts by beta-catenin ablation suppresses melanoma growth. Tumour Biol, 37, 14235–14248.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
